Breast Cancer Awareness Month::SoftScan® molecular breast imaging system - made in Canada
October 8, 2009
Breast Cancer Awareness Month is in full swing, and I would like to take this opportunity to introduce the SoftScan® breast imaging device, which is being commercialized in Canada and in Europe for a little over a year. This product, based on a truly innovative technology, brings hope to women affected by breast cancer. Our web site offers more detailed information at: http://www.art.ca/en/clinical/index.php
• Our company, ART Advanced Research Technologies Inc., is based in Montreal and designs and markets molecular imaging equipment that significantly improve the efficacy of treatments aimed at patients suffering from various diseases, particularly breast cancer.
• Using SoftScan, more rapid treatment monitoring of breast cancer treatment increases chances of a better prognostic.
• The SoftScan technology makes painless and risk-free diagnosis of breast cancer possible, earlier on.
• SoftScan is a non-invasive technology.
• The SoftScan technology platform, used in pharmaceutical settings, accelerates the discovery of new treatments and their arrival to market.
HOW IS SOFTSCAN BETTER THAN CURRENT METHODS?
Traditional anatomical breast imaging, such as mammography, does not capture biochemistry, physiology or the patient′s response to therapy until the anatomy changes. It has "blind spots" that fundamentally limit its diagnostic capabilities. The SoftScan device also has the capacity of detecting subtle vascular changes (angiogenesis) that are often associated with breast cancer. Finally, thanks to its safe, non-invasive and painless technology, there are no limits regarding how often the SoftScan can be used on a patient.
IN THE FUTURE, THE SOFTSCAN DEVICE COULD PROVE TO BE A PROMISING SOLUTION FOR WOMEN UNDER 40 YEARS OLD !
Women under 40 years old take a risk when having a mammography, particularly in the case of younger women who manifest denser tissues in their X-rays.
Meanwhile, taking X-rays too soon can be harmful to one′s health ans and contribute to the development of tumours. SoftScan emits no ionizing radiation, so any number of scans can be done without risk. This compares favourably with mammography, the use of which must be strictly limited. As a treatment-monitoring tool, therefore, SoftScan can allow oncologists to see immediately if a course of treatment is working and then adjust or interrupt treatment. This could lead to shorter treatments, less suffering, better results and lower costs for the health care system. Results from treatment monitoring pilot study conducted at Sunnybrook Health Sciences Centre in Toronto are expected to be published shortly in a peer-reviewed journal.
SOFTSCAN PROVIDES ADDED VALUE
The SoftScan device definitively provides added value, since in the breast cancer treatment sector, the costs on society have jumped from $22 billion in 2003 to $35 billion in recent years! One must take into consideration that a single treatment may sometimes cost up to $60,000. The use of this device, which provides for a more reliable and faster diagnosis, would considerably reduce the various interventions and would help improve the quality of the life of patients.
If this presentation is of interest to your media or if you have any questions, please do not hesitate to contact me, directly on my cell phone, at (514)889-0245.
Thanks for this opportunity, and your support to the breast cancer awareness message!For more information contact
ART Advanced Research Technologies Inc.